It's about co-funding industrial facilities for developing and
producing gene and cell therapies, and to build up a new economic sector.
Not exact matches
ORDINARY
cells from people with a genetic disease can be «fixed» by
gene therapy and then reprogrammed to be stem
cells that will
produce a limitless supply of defect - free
cells.
In the recessive deafness model,
gene therapy with TMC1 restored the ability of sensory hair
cells to respond to sound —
producing a measurable electrical current —
and also restored activity in the auditory portion of the brainstem.
For the animal experiments, Savio Woo of the Center for
Gene Therapy at Baylor College of Medicine in Houston
and his colleagues first isolated liver
cells from transgenic mice that
produce the human protein a1 - antitrypsin in their livers, from where it is secreted into the blood.
Many life - saving products, such as recombinant therapeutic proteins, vaccines,
and gene therapy vectors, are
produced from large - scale
cell culture systems.
In the health care industry, many life - saving products, such as recombinant therapeutic proteins, vaccines,
and gene therapy vectors, are
produced from large - scale
cell culture systems.
The technology also improves
cell culture systems used to
produce therapeutic proteins, vaccines,
and gene therapy vectors.
Some researchers seek
gene therapies that might act more broadly on retinal
cells, perhaps by using
genes that
produce proteins supporting the growth
and health of nerve
cells, which could be delivered before significant vision loss occurs.
The first step in both direct
and cell - based
gene therapy is packaging a therapeutic transgene into a delivery vehicle (e.g., a viral vector), followed by expansion of its host
cell lines to
produce high - enough vector concentrations.
In addition to its emphasis on
producing vaccines, the lab specializes in
gene and cell therapies, including stem
cell products.
«The Department of Health
and its
Gene Therapy Advisory Committee are currently working with other regulators in the field to
produce a «Regulatory Route Map» to provide further clarity on the regulatory requirements for the clinical use of stem
cells.»